Congenital HCMV infection is the most frequent congenital infection, with an incidence of 0.2-2.5% among all live births. About 11% of infected newborns show symptoms at birth, including hepatosplenomegaly, thrombocytopenia, neurologic involvement, hearing impairment and visual deficit. Moreover, 5-25% of the asymptomatic congenital HCMV-infected neonates will develop sequelae over months or even years. The relevant social burden, the economic costs of pre-natal screening, post-natal diagnosis, follow-up and possible therapy, although still limited, are the major factors to be considered. Several types of vaccines have been explored in order to develop an effective and safe HCMV vaccine: live attenuated, subunit, vectored, peptide, DNA, and subviral ones, but none are available for use. This review illustrates the different vaccine types studied to date, focusing on the possible vaccination strategy to be implemented once the HCMV vaccine is available, in terms of target population. Copyright © by BIOLIFE, s.a.s.

Is HCMV vaccine an unmet need? The state of art of vaccine development / Chiurchiu, S.; Calo Carducci, F. I.; Rocchi, F.; Simonetti, A.; Bonatti, G.; Salmaso, S.; Melchiorri, D.; Pani, L.; Rossi, P.. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - 26:1(2013), pp. 15-26.

Is HCMV vaccine an unmet need? The state of art of vaccine development

Pani L.;
2013

Abstract

Congenital HCMV infection is the most frequent congenital infection, with an incidence of 0.2-2.5% among all live births. About 11% of infected newborns show symptoms at birth, including hepatosplenomegaly, thrombocytopenia, neurologic involvement, hearing impairment and visual deficit. Moreover, 5-25% of the asymptomatic congenital HCMV-infected neonates will develop sequelae over months or even years. The relevant social burden, the economic costs of pre-natal screening, post-natal diagnosis, follow-up and possible therapy, although still limited, are the major factors to be considered. Several types of vaccines have been explored in order to develop an effective and safe HCMV vaccine: live attenuated, subunit, vectored, peptide, DNA, and subviral ones, but none are available for use. This review illustrates the different vaccine types studied to date, focusing on the possible vaccination strategy to be implemented once the HCMV vaccine is available, in terms of target population. Copyright © by BIOLIFE, s.a.s.
26
1
15
26
Is HCMV vaccine an unmet need? The state of art of vaccine development / Chiurchiu, S.; Calo Carducci, F. I.; Rocchi, F.; Simonetti, A.; Bonatti, G.; Salmaso, S.; Melchiorri, D.; Pani, L.; Rossi, P.. - In: INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY. - ISSN 0394-6320. - 26:1(2013), pp. 15-26.
Chiurchiu, S.; Calo Carducci, F. I.; Rocchi, F.; Simonetti, A.; Bonatti, G.; Salmaso, S.; Melchiorri, D.; Pani, L.; Rossi, P.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1211963
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact